NRG
JAZZ icon

Nemes Rush Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Nemes Rush Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189 Sell
1
-1
-50% -$175 ﹤0.01% 921
2025
Q4 		$340 Buy
+2
New +$307 ﹤0.01% 903

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Nemes Rush Group's JAZZ Position: Q1 2026 in Review

Nemes Rush Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 50% in Q1 2026, selling an estimated $175 and leaving 1 share worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Nemes Rush Group first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $340 in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Nemes Rush Group held 1 share of Jazz Pharmaceuticals worth $189 as of Q1 2026.
  • Nemes Rush Group sold 1 Jazz Pharmaceuticals share in Q1 2026, an estimated $175.
  • Jazz Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #921 holding.
  • Nemes Rush Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Nemes Rush Group's Jazz Pharmaceuticals position peaked at $340 in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.